| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib JA Woyach, RR Furman, TM Liu, HG Ozer, M Zapatka, AS Ruppert, L Xue, ... New England Journal of Medicine 370 (24), 2286-2294, 2014 | 1335 | 2014 |
| Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ... New England Journal of Medicine 379 (26), 2517-2528, 2018 | 942 | 2018 |
| Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study P Paschka, G Marcucci, AS Ruppert, K Mrózek, H Chen, RA Kittles, ... Journal of Clinical Oncology 24 (24), 3904-3911, 2006 | 855 | 2006 |
| Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia KJ Maddocks, AS Ruppert, G Lozanski, NA Heerema, W Zhao, L Abruzzo, ... JAMA oncology 1 (1), 80-87, 2015 | 636 | 2015 |
| MicroRNA expression in cytogenetically normal acute myeloid leukemia G Marcucci, MD Radmacher, K Maharry, K Mrózek, AS Ruppert, ... New England Journal of Medicine 358 (18), 1919-1928, 2008 | 539 | 2008 |
| BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ... Journal of Clinical Oncology 35 (13), 1437, 2017 | 475 | 2017 |
| Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t (8; 21) differ from those of patients with inv (16): a Cancer and Leukemia Group B … G Marcucci, K Mrózek, AS Ruppert, K Maharry, JE Kolitz, JO Moore, ... Journal of clinical oncology 23 (24), 5705-5717, 2005 | 447 | 2005 |
| Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk … G Marcucci, K Maharry, MD Radmacher, K Mrózek, T Vukosavljevic, ... Journal of clinical oncology 26 (31), 5078, 2008 | 377 | 2008 |
| Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia … SS Farag, KJ Archer, K Mrózek, AS Ruppert, AJ Carroll, JW Vardiman, ... Blood 108 (1), 63-73, 2006 | 364 | 2006 |
| FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal … SP Whitman, AS Ruppert, MD Radmacher, K Mrózek, P Paschka, ... Blood, The Journal of the American Society of Hematology 111 (3), 1552-1559, 2008 | 360 | 2008 |
| Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy JA Woyach, K Smucker, LL Smith, A Lozanski, Y Zhong, AS Ruppert, ... Blood, The Journal of the American Society of Hematology 123 (12), 1810-1817, 2014 | 341 | 2014 |
| Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study P Paschka, G Marcucci, AS Ruppert, SP Whitman, K Mrózek, K Maharry, ... Journal of Clinical Oncology 26 (28), 4595, 2008 | 335 | 2008 |
| DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia CC Oakes, M Seifert, Y Assenov, L Gu, M Przekopowitz, AS Ruppert, ... Nature genetics 48 (3), 253-264, 2016 | 320 | 2016 |
| BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study CD Baldus, SM Tanner, AS Ruppert, SP Whitman, KJ Archer, G Marcucci, ... Blood 102 (5), 1613-1618, 2003 | 310 | 2003 |
| Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study G Marcucci, CD Baldus, AS Ruppert, MD Radmacher, K Mrózek, ... J Clin Oncol 23 (36), 9234-9242, 2005 | 302 | 2005 |
| Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease TS Lin, AS Ruppert, AJ Johnson, B Fischer, NA Heerema, LA Andritsos, ... Journal of Clinical Oncology 27 (35), 6012, 2009 | 290 | 2009 |
| Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv (16)(p13q22) or t (16; 16)(p13; q22): results from CALGB 8461 JC Byrd, AS Ruppert, K Mrózek, AJ Carroll, CG Edwards, DC Arthur, ... Journal of Clinical Oncology 22 (6), 1087-1094, 2004 | 271 | 2004 |
| Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL) JA Woyach, E Bojnik, AS Ruppert, MR Stefanovski, VM Goettl, ... Blood, The Journal of the American Society of Hematology 123 (8), 1207-1213, 2014 | 258 | 2014 |
| High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal … C Langer, MD Radmacher, AS Ruppert, SP Whitman, P Paschka, ... Blood, The Journal of the American Society of Hematology 111 (11), 5371-5379, 2008 | 240 | 2008 |
| International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI AS Ruppert, JG Dixon, G Salles, A Wall, D Cunningham, V Poeschel, ... Blood, The Journal of the American Society of Hematology 135 (23), 2041-2048, 2020 | 237 | 2020 |
